Beyond the first trimester screen: Can we predict who will choose invasive testing?
- 1 June 2011
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 13 (6) , 539-544
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Nuchal translucency screening: how do women actually utilize the results?Prenatal Diagnosis, 2006
- Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trialsAmerican Journal of Obstetrics and Gynecology, 2006
- The influence of risk estimates obtained from maternal serum screening on amniocentesis ratesPrenatal Diagnosis, 2005
- Maternal serum biochemistry at 11-13+6 weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screeningPrenatal Diagnosis, 2005
- Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21American Journal of Obstetrics and Gynecology, 2005
- The impact of first-trimester screening on AMA patients' uptake of invasive testingPrenatal Diagnosis, 2005
- Second‐trimester maternal serum screening for Down syndrome in in vitro fertilization pregnanciesPrenatal Diagnosis, 2005
- A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β‐hCG and PAPP‐APrenatal Diagnosis, 2002
- Decisions about amniocentesis by advanced maternal age patients following maternal serum screening may not always correlate clinically with screening results: Need for improvement in informed consent processAmerican Journal of Medical Genetics, 2002
- A measure of informed choiceHealth Expectations, 2001